These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9155520)

  • 1. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study.
    Aravantinos G; Skarlos DV; Kosmidis P; Athanassiades A; Bafaloukos D; Giannakakis T; Karpathios S; Fountzilas G
    Eur J Cancer; 1997 Jan; 33(1):160-3. PubMed ID: 9071916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
    Guastalla JP; Lhommé C; Dauplat J; Namer M; Bonneterre J; Oberling F; Pouillart P; Fumoleau P; Kerbrat P; Tubiana N
    Ann Oncol; 1994; 5 Suppl 6():S33-8. PubMed ID: 7865432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Ball H; Hummel SJ; Barrett RJ
    J Clin Oncol; 1994 Sep; 12(9):1748-53. PubMed ID: 7916038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
    Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
    Tropé C; Hogberg T; Kaern J; Bertelsen K; Bjorkholm E; Boman K; Himmelmann A; Horvath G; Jacobsen A; Kuoppola T; Vartianen J; Lund B; Onsrud M; Puistola U; Salmi T; Scheistroen M; Sandvei R; Simonsen E; Sorbe B; Tholander B; Westberg R
    Ann Oncol; 1998 Dec; 9(12):1301-7. PubMed ID: 9932160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
    Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
    J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
    Tay SK; Thilagam MD
    Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
    ten Bokkel Huinink W; Lane SR; Ross GA;
    Ann Oncol; 2004 Jan; 15(1):100-3. PubMed ID: 14679127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
    Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
    Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
    Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
    Fleming GF; Waggoner SE; Rotmensch J; Langhauser C
    Am J Clin Oncol; 2001 Feb; 24(1):52-7. PubMed ID: 11232950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Vergote I; von Moos R; Manso L; Van Nieuwenhuysen E; Concin N; Sessa C
    Gynecol Oncol; 2018 Sep; 150(3):471-477. PubMed ID: 30060963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.